摘要
目的观察小剂量碘131辅助抗甲状腺药物治疗甲亢的临床效果。方法选取2016年10月至2019年10月我院收治的甲亢患者100例,随机分为实验组(n=50)与对照组(n=50)。两组均采用甲巯咪唑治疗,同时实验组给予小剂量(平均剂量为2.90 MBq/g)碘131治疗,对照组给予常规正常剂量(平均剂量为4.45 MBq/g)碘131治疗,治疗周期均为2个月。比较两组的临床疗效,治疗前后甲状腺肿大率(GR)、甲状腺球蛋白(Tg)水平及治疗后甲状腺功能减退情况。结果实验组治疗总有效率为90.00%,高于对照组的74.00%(P<0.05)。治疗前,两组的GR、Tg水平比较无统计学差异(P>0.05);治疗后,两组的GR、Tg水平均降低,且实验组的GR、Tg水平低于对照组(P<0.05)。治疗后,实验组甲状腺功能减退率为8.00%,低于对照组的24.00%(P<0.05)。结论小剂量碘131辅助抗甲状腺药物治疗甲亢临床效果显著,可有效改善患者甲状腺肿大,降低Tg水平,减少甲状腺功能减退情况,值得临床推广。
Objective To observe the clinical effect of low-dose iodine 131 and adjuvant antithyroid drugs in the treatment of hyperthyroidism.Methods 100 patients with hyperthyroidism admitted to our hospital from October 2016 to October 2019 were selected and randomly divided into experimental group(n=50)and control group(n=50).Both groups were treated with methimazole.At the same time,the experimental group was treated with low-dose(average dose of 2.90 MBq/g)iodine 131,and the control group was treated with conventional normal-dose(average dose of 4.45 MBq/g)iodine 131.The treatment period was 2 months.The clinical efficacy,the goiter rates(GR)and thyroglobulin(TG)levels before and after treatment,and the hypothyroidism after treatment were compared between the two groups.Results The total effective rate of treatment in the experimental group was 90.00%,higher than 74.00%in the control group(P<0.05).Before treatment,no statistical difference was found in GR and Tg level between the two groups(P>0.05).After treatment,the GR and Tg levels in the two groups decreased,and the GR and Tg level of the experimental group were lower than those of the control group(P<0.05).After treatment,the hypothyroidism rate of the experimental group was 8.00%,lower than the 24.00%of the control group(P<0.05).Conclusions Low-dose iodine 131 and adjuvant antithyroid drugs have significant clinical effect in the treatment of hyperthyroidism,and can effectively improve the goiter,and reduce the Tg level and hypothyroidism,which is worthy of clinical promotion.
作者
李娟
LI Juan(2nd Ward of Endocrinology and Metabolism Department,Jiaozuo People's Hospital,Jiaozuo 454150,China)
出处
《临床医学工程》
2021年第3期321-322,共2页
Clinical Medicine & Engineering